Moxetumomab pasudotox  (Synonyms: CAT 8015; HA 22; Anti-Human CD22 Recombinant Antibody)

Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 F_v and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL)^[1][2][3].

Moxetumomab pasudotox (0-10 mg/mL, 66 h) reduces cell viability of BCP-ALL cells (determined by Annexin-V negative)^[3].
The binding and internalization of MP/CD22 complexes is correlated with pre-B ALL cell line responses to MP^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Moxetumomab pasudotox (300 mg/kg, i.v., every other day) prolongs median survival in 697 cell model (P < 0.0001)^[3].
Moxetumomab pasudotox (0.4 mg/kg, i.v. three doses, every other day) clears the bone marrow (BM) from acute lymphoblastic leukemia (ALL), but disease relapses from discrete BM-sites in NSG mouse model^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

63.5 (kDa)

1020748-57-5

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kreitman RJ, et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2021 Feb 24;14(1):35.  [Content Brief]

  [2]. hillon S. Moxetumomab Pasudotox: First Global Approval. Drugs. 2018 Nov;78(16):1763-1767.  [Content Brief]

  [3]. Kinjyo I, et al. Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017 Nov;64(11):10.1002/pbc.26604.  [Content Brief]

  [4]. Müller F, et al. 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox. Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):E1867-E1875.  [Content Brief]

  [5]. Ksenia Matlawska-Wasowska, et al. Variability In Precursor B ALL Killing With Moxetumomab Pasudotox (CAT-8015) Linked To Differential Binding and Endocytic Trafficking. Blood (2013) 122 (21): 5022.